Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 3
1(100.0%)
1Total
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT03751072Completed

Efficacy and Toxicity of Blinatumomab in the French ATU for Adult BCP-ALL R/R, or With MRD+ (FRENCH-CYTO)

Role: lead

NCT07433400Recruiting

Long-term Progression of Patients Treated and Monitored for Relapsed or Refractory Ph+ ALL

Role: lead

NCT04452604Completed

Multicentric Registry of Patients With Acute Leukemia Infected by COVID-19

Role: collaborator

NCT00327678Phase 3Completed

Treatment of Acute Lymphoblastic Leukemia (ALL) in Younger Adults

Role: collaborator

All 4 trials loaded